UY37931A - CONTIGATES OF ANTI-CD71 ACTIVABLE ANTIBODY AND DRUG AND ITS METHODS OF USE - Google Patents

CONTIGATES OF ANTI-CD71 ACTIVABLE ANTIBODY AND DRUG AND ITS METHODS OF USE

Info

Publication number
UY37931A
UY37931A UY0001037931A UY37931A UY37931A UY 37931 A UY37931 A UY 37931A UY 0001037931 A UY0001037931 A UY 0001037931A UY 37931 A UY37931 A UY 37931A UY 37931 A UY37931 A UY 37931A
Authority
UY
Uruguay
Prior art keywords
methods
contigates
drug
activable antibody
antibodies
Prior art date
Application number
UY0001037931A
Other languages
Spanish (es)
Inventor
Shweta Singh
Jennifer Hope Richardson
Laura Patterson Serwer
Jonathan Alexander Terrett
Susan E Morgan-Lappe
Tracy Henriques
Sherry L Ralston
Marvin Robert Leanna
Ilaria Badagnani
Sahana Bose
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY37931A publication Critical patent/UY37931A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere generalmente a anticuerpos activables conjugados que se unen a CD71 en su forma activa y a los métodos de preparación y uso de estos anticuerpos activables conjugados anti-CD71 en una variedad de indicaciones terapéuticas, diagnósticas y profilácticas.The invention generally relates to conjugated activatable antibodies that bind to CD71 in its active form and to the methods of preparation and use of these activated conjugated anti-CD71 antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

UY0001037931A 2017-10-14 2018-10-12 CONTIGATES OF ANTI-CD71 ACTIVABLE ANTIBODY AND DRUG AND ITS METHODS OF USE UY37931A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14

Publications (1)

Publication Number Publication Date
UY37931A true UY37931A (en) 2019-04-30

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037931A UY37931A (en) 2017-10-14 2018-10-12 CONTIGATES OF ANTI-CD71 ACTIVABLE ANTIBODY AND DRUG AND ITS METHODS OF USE

Country Status (34)

Country Link
US (3) US20190111150A1 (en)
EP (2) EP3834846A1 (en)
JP (2) JP7374891B2 (en)
KR (4) KR102529359B1 (en)
CN (1) CN111278467B (en)
AR (1) AR115178A1 (en)
AU (1) AU2018346969A1 (en)
BR (1) BR112020007302B1 (en)
CA (1) CA3077730A1 (en)
CL (1) CL2020000977A1 (en)
CO (1) CO2020005685A2 (en)
CR (1) CR20200206A (en)
CY (1) CY1123968T1 (en)
DK (1) DK3691692T3 (en)
DO (1) DOP2023000150A (en)
EC (1) ECSP20025198A (en)
ES (1) ES2864013T3 (en)
HR (1) HRP20210436T8 (en)
HU (1) HUE054037T2 (en)
IL (1) IL273586A (en)
LT (1) LT3691692T (en)
MA (1) MA50752B1 (en)
MD (1) MD3691692T2 (en)
MX (1) MX2020003723A (en)
PE (1) PE20210125A1 (en)
PL (1) PL3691692T3 (en)
PT (1) PT3691692T (en)
RS (1) RS61596B1 (en)
RU (2) RU2022111211A (en)
SG (1) SG11202003378WA (en)
SI (1) SI3691692T1 (en)
TW (2) TW202330039A (en)
UY (1) UY37931A (en)
WO (1) WO2019075417A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
PL3292149T3 (en) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
WO2021205358A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Compositions and methods for blood-brain barrier delivery
BR112022019841A2 (en) * 2020-04-09 2022-12-06 Cytomx Therapeutics Inc COMPOSITIONS CONTAINING ACTIVABABLE ANTIBODIES
EP4429654A1 (en) 2021-11-09 2024-09-18 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2024026474A1 (en) * 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
KR101811965B1 (en) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. Antibodies that bind human dendritic and epithelial cell 205(dec-205)
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2010126972A1 (en) * 2009-04-29 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Erg monoclonal antibodies
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
EP2670440B1 (en) * 2011-02-01 2018-09-05 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
PL3431504T3 (en) * 2012-01-31 2021-10-18 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (en) * 2013-02-05 2014-05-21 浙江大学 Anti-CD20 antibody-monomethyl auristatin E conjugate, preparation method and application thereof
WO2015098099A1 (en) * 2013-12-25 2015-07-02 第一三共株式会社 Anti-trop2 antibody-drug conjugate
PL3292149T3 (en) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
CN106237341B (en) * 2016-07-12 2019-07-30 浙江大学 A kind of antibody coupling drug and its preparation method and application

Also Published As

Publication number Publication date
TW202330039A (en) 2023-08-01
HUE054037T2 (en) 2021-08-30
PT3691692T (en) 2021-03-29
MD3691692T2 (en) 2021-05-31
CR20200206A (en) 2021-02-18
JP2024012366A (en) 2024-01-30
RU2020115713A3 (en) 2022-02-25
RS61596B1 (en) 2021-04-29
KR20230004932A (en) 2023-01-06
WO2019075417A1 (en) 2019-04-18
ES2864013T3 (en) 2021-10-13
CN111278467A (en) 2020-06-12
SI3691692T1 (en) 2021-04-30
EP3691692B1 (en) 2020-12-30
RU2022111211A (en) 2022-05-05
RU2020115713A (en) 2021-11-16
SG11202003378WA (en) 2020-05-28
US20210145978A1 (en) 2021-05-20
KR102529359B1 (en) 2023-05-09
HRP20210436T8 (en) 2022-01-07
HRP20210436T1 (en) 2021-04-30
KR102385495B1 (en) 2022-04-15
IL273586A (en) 2020-05-31
CY1123968T1 (en) 2022-05-27
US20190111150A1 (en) 2019-04-18
EP3834846A1 (en) 2021-06-16
DOP2023000150A (en) 2023-08-31
JP2020537649A (en) 2020-12-24
TWI780237B (en) 2022-10-11
RU2771292C2 (en) 2022-04-29
PL3691692T3 (en) 2021-07-19
TW201927815A (en) 2019-07-16
MA50752B1 (en) 2021-03-31
AU2018346969A1 (en) 2020-04-23
MA50752A (en) 2020-08-12
AR115178A1 (en) 2020-12-09
DK3691692T3 (en) 2021-03-22
BR112020007302A2 (en) 2020-09-29
CA3077730A1 (en) 2019-04-18
ECSP20025198A (en) 2020-06-30
LT3691692T (en) 2021-05-10
KR20200070324A (en) 2020-06-17
JP7374891B2 (en) 2023-11-07
CN111278467B (en) 2024-07-30
CL2020000977A1 (en) 2020-09-11
EP3691692A1 (en) 2020-08-12
KR20230070046A (en) 2023-05-19
CO2020005685A2 (en) 2020-05-15
BR112020007302B1 (en) 2023-01-31
MX2020003723A (en) 2020-07-22
EP3691692B8 (en) 2021-05-26
PE20210125A1 (en) 2021-01-19
KR20220045088A (en) 2022-04-12
US20240115724A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
UY37931A (en) CONTIGATES OF ANTI-CD71 ACTIVABLE ANTIBODY AND DRUG AND ITS METHODS OF USE
BR112017023862A2 (en) anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of using these
CL2020001048A1 (en) Monoclonal antibodies against bcma. (divisional request 201800281)
AU2018278327A1 (en) Activatable anti-pdl1 antibodies and methods of use thereof
CL2017003261A1 (en) Factor xi antibodies and methods of use
UY37779A (en) ANTIBODY MOLECULES THAT JOIN CD73 AND USES OF THE SAME
CL2017000704A1 (en) Therapeutic agent that induces cytotoxicity
MX2021005116A (en) Activatable anti-cd166 antibodies and methods of use thereof.
CO2017005650A2 (en) Anti-interleukin-33 antibodies
BR112018014760A2 (en) anti-ror1 antibodies, bispecific antibodies to ror1 x cd3 and methods of use
BR112017023872A2 (en) anti-cd166 antibodies, activatable anti-cd166 antibodies and methods of use
CO2018004152A2 (en) Antibody-pyrrolobenzodiazepine drug conjugates and methods of use
CR20160437A (en) CONJUGATES OF ANTI-DROSOPHILA ANTIBODIES SIMILAR TO DELTA 3 (ANTI-DLL3) AND MEDICINES FOR USE IN THE TREATMENT AGAINST MELANOMA
CO2020012360A2 (en) Multispecific antibodies and their use
UY35478A (en) DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-1ß and / or IL-17
CO2020012524A2 (en) Antibodies
CL2023000701A1 (en) Antibodies that bind to il1rap and their uses
MX2020009130A (en) Therapeutic anti-spla2-gib antibodies and the uses thereof.
CL2023001064A1 (en) Anti-steap1 antigen binding protein
UY37598A (en) MIMETIC ANTIBODIES OF FGF21 AND USES OF THE SAME
UY39337A (en) ANTI-ABETA ANTIBODIES
CO2021015462A2 (en) Antibodies and formulations of anti-cd38
CL2023000971A1 (en) Steroids and protein conjugates thereof.
AR116101A1 (en) ANTI-STEAP1 ANTIGEN BINDING PROTEIN
AR118756A1 (en) ANTIBODIES AND ANTI-CD38 FORMULATIONS